Clinical Trials Logo

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03592576
Study type Expanded Access
Source AbbVie
Contact ABBVIE CALL CENTER
Phone 847.283.8955
Email abbvieclinicaltrials@abbvie.com
Status Available
Phase

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Recruiting NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Withdrawn NCT01994200 - Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients Phase 1/Phase 2
Recruiting NCT01964508 - microRNA in Thyroid Cancer N/A
Completed NCT01728623 - A Study of E7080 in Subjects With Advanced Thyroid Cancer Phase 2
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00970359 - Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 N/A
Completed NCT00439478 - Dental Safety Profile of High-Dose Radioiodine Therapy Phase 4
Completed NCT00223158 - Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer N/A
Recruiting NCT03246958 - Nivolumab Plus Ipilimumab in Thyroid Cancer Phase 2
Active, not recruiting NCT02223052 - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Phase 1
Recruiting NCT03065218 - Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients N/A
Active, not recruiting NCT02953288 - Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules. N/A
Recruiting NCT02225509 - Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology N/A
Recruiting NCT02390934 - Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer Phase 2
Active, not recruiting NCT02084732 - Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study Phase 2
Completed NCT01438554 - Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Phase 1
Completed NCT00887107 - Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Phase 2